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ABSTRACT
OBJECTIVE: To analyze the clinical and laboratory 
features of Multiple Myeloma at presentation in a 
tertiary centre in  Port Harcourt, Southern Nigeria.
METHODS: The medical records of all patients 
diagnosed for plasma cell neoplasia within a 10 year 
period at the University of Port Harcourt Teaching 
Hospital were reviewed retrospectively.  Clinical 
presentation, investigation results, support and specific 
therapy used were documented.
RESULTS: A total of 20 patients were diagnosed with 
multiple myeloma, 70% were males, the mean age was 
61.30 + 8.8 years, 50% of them had pathological 
fractures. The mean duration before presentation was  
11.89  + 11.7 months (Median = 7 months) and 
associated with poor outcome.  The most common 
method of treatment was chemotherapy with Melphalan 
and Prednisolone.
CONCLUSION:  MM is a disease of the elderly that 
can negatively impact on the quality of life due to the 
complications associated with it.   A long duration of 
symptoms before presentation is a common problem and 
it has been associated with substantial morbidity and 
mortality in this study.
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INTRODUCTION
Multiple Myeloma (MM) is a common haematological 
malignancy and it is characterized by the clonal 
proliferation of plasma cells in the bone marrow with 
accompanying increased levels of monoclonal proteins 
(M-proteins) in urine and/or blood. It is usually preceded 
by premalignant conditions Monoclonal Gammopathy 
of Undertermined Significance (MGUC) or Smoldering 
Myeloma (SM) which also have proliferation of plasma 
cells and M-proteins however they are asymptomatic 
and lack end organ involvement., The underlying 
pathophysiologic mechanism involves both numerical 
and structural genetic alteration, resulting from 
hyperdiploidy or translocation. Hyperdiploidy in 
Myeloma usually involves non-random trisomies of odd 
numbered chromosomes 3,5,7,9,11,15,19 and 21. 
Translocation involves the IgH gene during 
immunoglobul in  c lass  swi tch ing ,  somat ic  
hypermutation or rearrangement of the variable, 
diversity and joining genes (VDJ rearrangement), which 
are required for the production of highly specialized 
antibodies. There are 5 recurrent translocations 
involving the IgH gene accounting for about half of the 
genetic abnormalities in Myeloma. This aberrant 
recombinations juxtapose oncogenes involved in cell 
proliferation or survival to close proximity of the 
powerful transcriptionally active IgH gene, giving rise 
to a neoplastic terminally differentiated B-cell that 
,homes to the bone marrow.  The myeloma cell actively 
interacts with the bone marrow microenvironment and is 
dependent on it for its survival and drug resistance. 
When the myeloma cell adheres to the bone marrow 
stroma, it induces secretion of various cytokines and 
growth factors, including interleukin 6 (IL-6) and 
Osteoclast activating factor (OAF). The secreted OAF 
induces the stroma and osteoblasts to produce receptor 
activator of Nuclear Factor-êB ligand (RANKL), which 
stimulates osteoclast activity for bone destruction. This 
in turn causes increased release of cytokines from the 
bone matrix and these cytokines continue to stimulate 
growth of the myeloma cell. RANKL is inhibited by 
Osteoprotegerin (OPG), however CD138 (Syndecan-1) 
on the myeloma cell traps OPG and internalizes it. The 
myeloma cell also adheres to the extracellular matrix 
proteins to cause upregulation of cytokines involved in 
angiogenesis e.g. IL-6. Imbalance of osteoclast bone 
resorption and osteoblast bone formation results in bone 
,disease.   The clinical features of multiple myeloma are 
variable and include anemia, low back pain, 
pathological fractures, neuropathy, hyperviscosity, 
recurrent infections and amyloidosis.  The diagnostic 
criteria of multiple myeloma requires bone marrow 
plasmacytosis, presence of M-protein and related organ 
tissue impairment which manifests as hypercalcaemia 
(C), renal insufficiency (R), anaemia (A) or bone disease 
8(B) which constitute the CRAB syndrome.   
Overwhelming predictors of prognosis include albumin, 
2-microglobulin, and chromosomal karyotype.
Some studies have been carried out to analyze the 
clinical presentation and the laboratory findings of MM 
in Nigeria. The aim of this study is to determine the 
pattern of clinical and laboratory features of MM 
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Study design: All cases of Multiple Myeloma seen in  
UPTH from January 2003  January 2013 were reviewed. 
The clinicopathological and demographic features of 
these patients extracted included the name, age, sex, 
occupation, history of exposure to chemicals at work, 
presenting features, Eastern Cooperative Oncology 
Group (ECOG) performance status, staging according 
to Durie and Salmon criteria. A diagnosis of MM was 
made using standard criteria of qualitative and/or 
quantitative abnormalities in the bone marrow plasma 
cells, presence of malignant forms (multinucleated, 
flame cells, mott cells and plasmablasts), characteristic 
osteolytic lesions on plain radiograph and monoclonal 
gammopathy in serum or urine. Results of Full Blood 
Count (FBC), Erythrocyte Sedimentation Rate (ESR), 
Electrolytes, Urea and Creatinine (EUC), Total Protein 
(TP) and Albumin were extracted; results of Bone 
Marrow Aspiration (BMA) and x-ray done for the 
patients were also retrieved.  These data was analyzed 
using SPSS Version 17.0, released in August 2008.
RESULTS
A total of 20 patients were seen in the haematology 
department of UPTH in the 10 year period January 2003  
January 2013. Seventy percent of them were males. The 
mean age at presentation was 61.30 yrs, and the median 
was 61.50yrs and a range of 45-78yrs. The mean 
duration of presentation after onset of symptoms was 
2
11.89 months and a range of 1-48 months . Twenty 
percent of them had history of exposure to chemicals  
Agrochemical, spray paint, rubber industry. The odds of 
those exposed to chemicals having poorer outcome was 
0.013 (P value = 0.0123).  This may associated with the 
fact that we have a small sample size.
Ninety percent of them had Multiple Myeloma, 5% each 
were plasma Cell Leukemia and Extramedullary 
Plasmacytoma respectively.  Average duration before 
Presentation was 11.9 months, a range of 1- 48 months. 
As at the time of this review 40% of the cases were dead, 
25% were lost to follow-up.  The patients that had longer 
duration of symptoms before presentation had poorer 
outcome, there was a positive statistical correlation 
between this two variables (r = 0.557, P = 0.013).
The clinical presentations of the patients are shown in 
figure 1. some of these symptoms include bone pain, low 
back pain, weakness, fever, weight loss, inability to 
work and bleeding.  The most common presentation was 
bone pain in 16 (80%) of the cases, weakness was 
associated with anaemia which was found in 14 (70%) 
of the patients, 7 (35%) of the patients presented with 
inability to walk which was as a result of pathological 
fractures. Ten (50%) of the cases presented with 
fractures affecting either the vertebrae, upper or lower 
limbs, ribs. Seven (35%) had evidence of infections 
commonly chest and joint infections. Bleeding (15%), 
abdominal complications (10%) and severe renal 
affectation requiring dialysis were quite infrequent in 
our case.  There was one case of frontal lobe CNS 
involvement and urinary bladder plasmacytoma as extra 
medullary manifestation. Generally, the performance 
status as evaluated by ECOG scale showed that 70% of 
the cases were at a low level of activity (2-4) at 
presentation. 
FIGURE1  Clinical Features 
Haematologic findings
All the patients had Bone Marrow Aspiration (BMA) for 
diagnosis, save 1 that had BMB because the BMA 
produced a 'dry tap'.  The mean marrow plasmacytosis 
was 38.5% a range of 5-70%.  However in all the cases, 
there were malignant forms such as multinucleated 
forms, plasmablasts or flame cells. The patient that had 
Bone Marrow Biopsy (BMB) showed sheets of plasma 
cells in the core of bone with depressed erythropoiesis.
On evaluating the FBC at presentation, mean 
haemoglobin was 7.8g/dl. Anaemia was seen in 88% of 
the cases at presentation and it was mostly moderate to 
severe anaemia. There was a negative Pearson 
correlation (r = - 0.176), between the duration of 
symptoms before presentation and severity of anaemia 
which was not statistically significant.  However, lower 
Hb was associated with poorer outcome which was 
statistically significant (P= 0.035). ESR was elevated in 
all cases; other haematologic indices are in Table 1 .
TABLE 1  Haematology findings
B i o c h e m i c a l  V a l u e s  T h e  S e r u m  P r o t e i n  
Electrophoresis showed monoclonal gammopathy in 10 
Sex Mean Median Range 
Heamoglobin(g/dl) 7.8 7.5 2.7-15.3 
Total WBC( x109/L) 7.9 5.6 1.70  24.80 
Platelet count( x109/L) 188.55 168 27  367 
ESR (mm/Hr) 126.9 150 59  170 
226
Nigerian Journal of Medicine, Vol. 22 No. 3, July - September, 2013, ISSN 1115 - 2613
(83.3%) of the 12 patients that had their results 
documented. Of the 9 cases that assayed for Bence Jones 
Proteins (BJP) in urine, 8 of them were positive. The 
findings of the blood chemistry are as follows.
TABLE 2  Biochemical findings
Conventional radiography
Among the 15 patients with radiographic data, 9 (60%) 
had osteopenic bones, 5 (33.3%) had osteolytic lesions, 
10(66.7%) had evidence of pathologic fracture.  6(60%) 
of these were in the vertebrae. Others affected the long 
bones, ribs and clavicle. One case however had a cranial 
involvement which was diagnosed by CT scan and was 
treated with radiotherapy 
Chemotherapeutics and surgical intervention
The chemotherapeutic combinations used in our centre 
inc lude  Melpha lan  +  Pred icoso lone(MP) ,  
Cyclophosphamide + Predinisolone(CP), Vincristine + 
A d r y i a m y c i n  + D e x a m t h a s o n e ( VA D ) ,  
Cyclophosphamide +Vincristine +Adryiamycin 
+Predisolone(CVAP), Bortezomib + Melphalan 
+Prednisolone(VMP) at the recommended doses. 
Nine(45%) of the cases were on MP, 4(20%) were given 
BMP, 2(10%) were on CP, 1(5%) on VAD and 1(5%) on 
CVAP.  Two of the patients with relapse after MP, had 
thalidomide added to their therapy with good response. 
Another case of relapse after MP was treated with 
weekly Bortezomib with good control of the disease.  
40% of these patients were not eligible for 
3transplantation due to either age , Serum Creatinine > 
3221umol/L  and ECOG status >3 or 4, not due to bone 
2pain .
Three of the patients did not commence chemotherapy 
either due to early demise while being optimized to 
commence chemotherapy on admission or the fact that 
they were unable to afford the drugs, so they left the 
hospital and never returned for follow-up. 
One patient received radiotherapy for frontal lobe 
plasmacytoma with a good outcome (follow-up brain 
CT after 1 year showed no progression of the tumor).  
Other medications used were bisphosphonates in 8 of 
the patients. 
Surgical intervention given included conservative 
management of intestinal obstruction/ileus in 2 cases by 
the general surgeons, a partial cystetomy was done for 1 
patient who had urinary bladder plasmacytoma by the 
urologist.  The orthopedic surgeons provided throraco-
lumbar jackets for 3 patients at risk of vertebral collapse.  
More invasive interventions were in the form of 
craniotomy and curettage for 1 case, 3 cases had 
insertion of plates to immobilize pathological fractures 
of the femur. Synovectomy was done for 1 patient with 
severe septic arthritis of the knee.
An average of 5.56 units of blood was transfused to 9 of 
the cases, (a total 50 units, and range of 2-10 units).  
Erythropoietin was found to improve quality of life and 
reduce transfusion dependence in 6(30%) of the 
patients.
Stage and Course of disease
Mortality was common in patients that presented late 
(10-24 months after the onset of symptoms) or with 
multiple fractures affecting the vertebrae, ribs and long 
bone and anaemia (Hb <6g/dl). The patients that are stiil 
alive had a short duration of symptoms before 
presentation (mean  7 months), Hb 9.7g/dl and fewer 
Skeletal Related Events.
DISCUSSION
MM is a haematologic malignancy characterized by 
clonal proliferation of immunoglobulin secreting 
plasma cells in the bone marrow. It is mainly a disease of 
the elderly and has steep increase in the incidence with 
advancing age after 50 years. However, younger ages of 
incidence have been reported. 
In our experience, the male to female ratio of incidence 
thwas 2.3:1.  MM occurred mostly in the elderly in the 6  
thto 7  decade of life.  The median age at representation 
(61yrs) in our analysis was similar to that reported in Ile-
3 2ife, (60yrs) , but higher than reports from Benin (54yr) ; 
India (55yrs). Some reports are higher than ours, such as 
7
reports from Ibadan (65yrs) and Europe (70yrs)  .  
Many of the patients presented late (6-12 months after 
onset of symptoms) and this was associated with poorer 
Performance status (ECOG 2-4 in 70% of cases), there 
was a positive correlation between these two variables (r 
= 0.422) although it was not statistically significant.  
The mean time of follow up was 8.86 months (median 
2.6, range 1-44 months). Skeletal-related events (SREs) 
are common in patients with osteolytic lesions from MM 
and result in substantial morbidity. Pathological 
fractures (PF) occur in 40% of patients with MM, 
however in our case, 50% of the patients had 
pathological fractures.  PF results from direct deposition 
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Index Mean Range 
Ca2+  2.06 1  3 
K+ 4.01 3  5 
Urea 27.26 2 -293 
Creatinine 181.14 70 -910 
Total protein  83 61  118 
Albumin  30.85 18  47 





of myeloma cells within the bone, also there is release of 
cytokines from the tumor and the bone marrow 
microenvironment leading to osteoclastic activity and 
bone resorption. In our patients, vertebral fractures were 
found to be more common (60%) than non-vertebral 
fractures, this is comparable with a report by Sonmez et 
al .  PFs are associated with reduced survival and 
10,
increased mortality in MM patients in some studies , 
however in our study, there was only a weak positive 
relationship (r = 0.212) which was not statistically 
significant.
Considering the fact that many patients present late with 
advanced disease, supportive care should be a major 
component of the treatment.  Red cell transfusion to 
correct anaemia and then rHuEPO to reduce transfusion 
dependence; plasmapheresis to reduce circulating 
paraprotein; bisphosphonates to inhibit bone resorption 
and surgical treatment of PF has been found to be useful 
in improving survival.
The mainstay of the treatment of MM today is 
chemotherapeutics and Stem cell transplantation.  The 
availability of novel agents such as thalidomide, 
bortezomib and lenalidomide has expanded the 
treatment options and has improved the outcome of 
patients with MM.  The oral combination of melphalan 
and prednisolone has been the standard treatment for 
2,3patients with MM in most centres in Nigeria .  
MP is also the most commonly used combination in our 
centre and with good control of the disease. However a 
few patients default from regular chemotherapy due to 
the financial burden and some relapse. The clinical 
outcome of our patients has improved with the addition 
bortezomib to MP in our treatment plan for those with a 
relapse after MP-only treatment or as part of the first line 
of treatment.  We have noticed an improved quality of 
life and faster relief of symptoms such as bone pain and 
anaemia. They are also now able to support themselves 
in some activities at home such feeding, bathing and 
doing light laundry within a short duration of treatment. 
However, the cost of this drug has been a huge burden on 
those that have accepted the option of adding it to their 
therapy because of its advantage.
In conclusion, MM is a disease of the elderly that can 
negatively impact on the quality of life due to the 
complications associated with it.  Early investigation of 
patients with bone pains and low back pain may be 
helpful to detect, monitor, follow-up and treat early 
disease to achieve a better outcome. Active supportive 
care in a multidisciplinary approach will also impact 
positively on survival of these cases.
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